Program
pamvatamig
Also written as “MCLA-129” and “MCLA-129: 1500mg or 2000mg IV Q2W”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticals | 44 open or running | phase 2since May 31, 2021 | May 31, 2021 | Apr 2028phase 2 · NCT06885840 |
| Genmab | 10 open or running | phase 2since Apr 9, 2021 | Apr 9, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 9, 2021First study: phase 2 study in Stomach NeoplasmsNew to GenmabGenmab · NCT04868877 · 194 enrolled · United States, Belgium, France and more
- May 31, 2021Betta Pharmaceuticals's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT04930432 · 400 planned · China
- Aug 21, 2023Phase 1 study in Non-Small Cell Lung Cancer、EGFR Sensitive MutationBetta Pharmaceuticals · NCT06015568 · 172 planned · China
- Mar 14, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT06885840 · 100 planned · China
- Jan 31, 2026Phase 2 study in Solid Advanced TumorBetta Pharmaceuticals · NCT07448116 · 164 planned · China
- Oct 26, 2026Phase 2 study terminatedStudy stoppedNCT04868877 · “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefi…”
- Oct 26, 2026Primary completion moved from 2026-03 to 2026-10-01Date moved laterphase 2 · +7 months · NCT04868877
Ahead
- Apr 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT06885840
- Apr 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT04930432
- Nov 4, 2028Primary completion: phase 1 study in Non-Small Cell Lung Cancer、EGFR Sensitive MutationBetta Pharmaceuticals · NCT06015568
- Feb 1, 2029Primary completion: phase 2 study in Solid Advanced TumorBetta Pharmaceuticals · NCT07448116
TargetBeta
“A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07448116Solid Advanced Tumor · China | 2 | Recruiting | Betta Pharmaceuticals | Feb 1, 2029 | 164 |
| NCT06885840Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Betta Pharmaceuticals | Apr 2028 | 100 |
| NCT06015568Non-Small Cell Lung Cancer、EGFR Sensitive Mutation · China | 1 | Not yet recruiting | Betta Pharmaceuticals | Nov 4, 2028 | 172 |
| NCT04930432Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Betta Pharmaceuticals | Apr 30, 2028 | 400 |
| NCT04868877Stomach Neoplasms · United States, Belgium, France and more | 2 | Terminated | Genmab | Oct 1, 2026 | 194 |
How it is read
Names in the registry
- “MCLA-129”, 4 entries
- “MCLA-129: 1500mg or 2000mg IV Q2W”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.